How do you pay?

How to pay the least

Cash price

$490+ for 30 tablets

Pharmacies pay about this for Gemtesa; you’d pay more.

  1. Ask your pharmacy for Gemtesa’s cash price, and one or two other pharmacies too.

Has to be Gemtesa? With Optum Perks’ free coupon, Target (CVS) lists it for $551 for 30 tablets without insurance.

Get the free Optum Perks coupon 

No generic is sold yet.

Compare every option

Question
Brand nameGemtesa
Authorized genericvibegron
Regular genericvibegron
What you’d pay
At least$490for 30 tablets; pharmacies pay this
Not soldThere isn’t one
Not soldNone sold yet
Same as Gemtesa?
The original
–
–

Brand nameThe maker’s card

GEMTESA Simple Savings Program

Savings card from Sumitomo Pharma America

Gemtesa’s maker has a savings program. Check its page for today’s terms.

Sign up on gemtesa.com 

Or call 1-833-876-8268.

From the maker’s site, checked October 26, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Brand nameWith a free discount coupon

Optum Perks, Optum’s free discount coupon, lists these prices for Gemtesa without insurance. Show the coupon from its page at the pharmacy; it can’t be used with insurance.

From Optum Perks, read November 2, 2026, with no location set. Its page opens on this dose; other doses and pharmacies near you are priced there too. With insurance, check your co-pay first: it may be lower.

Authorized genericNot sold

There isn’t one. An authorized generic is Gemtesa itself, from the same company, sold without the brand name, and usually for less. For now Gemtesa is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Gemtesa’s cash price, or your plan what it charges.

See the brand name →

What it’s used for

What the FDA label says

GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of:

  • overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
  • overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).

Source: the FDA label for Gemtesa (Sumitomo Pharma America, Inc.), April 1, 2025. Full label on DailyMed 

Good to know